# Sean Cao

> Sean Cao is a Series B investor at MLAB Biosciences backing Medical. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: MLAB Biosciences
- Total investments: 2
- Last investment: Apr 2022
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/sean-wuxiong-cao-05772a4

Sean Cao is a Series B investor at MLAB Biosciences focused on Medical and Biotechnology. Sean Wuxiong Cao is based out of Greater Boston and is the CEO and Co-Founder of MLAB Biosciences. Sean previously worked at Everest Medicines as a CEO and Co-Founder. Sean Wuxiong Cao attended the Wharton School.

## Contacts

5 contacts available for Sean Cao: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/sean-wuxiong-cao?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 100% |
| Biotechnology | 2 | 100% |
| Health Care | 1 | 50% |
| Product Research | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Series C | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Singapore | 1 | 50% |
| United States | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| RVAC Medicines | RVAC Medicines is a mRNA platform company engaged in the research and development of innovative products such as vaccines for diseases. | $140M | Series B | Apr 26, 2022 |  |
| NiKang Therapeutics | NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development ofproprietary drug candidates with the most desirable pharmacological features into clinical studies. | $200M | Series C | May 26, 2021 |  |

2 of 2 investments shown.

## Co-investors
- [Pavilion Capital](https://shizune.co/investors/profile/pavilion-capital) — VC Fund, 2 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 1 deal together
- [BlackRock](https://shizune.co/investors/profile/blackrock) — VC Fund, 1 deal together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 1 deal together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 1 deal together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 1 deal together

## About MLAB Biosciences

VC Fund



1 contacts available at MLAB Biosciences.

| Name | Title | Profile |
| --- | --- | --- |
| Sean Cao | CEO and Co-Founder | — |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Sean Cao invest in?

Sean Cao invests primarily in Medical, Biotechnology and Health Care startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Sean Cao?

Public channels for Sean Cao include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Sean Cao last invest?

The most recent investment recorded for Sean Cao closed in Apr 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co